Literature DB >> 21704617

Progesterone attenuates astro- and microgliosis and enhances oligodendrocyte differentiation following spinal cord injury.

Florencia Labombarda1, Susana González, Analia Lima, Paulina Roig, Rachida Guennoun, Michael Schumacher, Alejandro F De Nicola.   

Abstract

Reactive gliosis, demyelination and proliferation of NG2+ oligodendrocyte precursor cells (OPC) are common responses to spinal cord injury (SCI). We previously reported that short-term progesterone treatment stimulates OPC proliferation whereas chronic treatment enhances OPC differentiation after SCI. Presently, we further studied the proliferation/differentiation of glial cells involved in inflammation and remyelination in male rats with SCI subjected to acute (3 days) or chronic (21 days) progesterone administration. Rats received several pulses of bromodeoyuridine (BrdU) 48 and 72 h post-SCI, and sacrificed 3 or 21 days post-SCI. Double colocalization of BrdU and specific cell markers showed that 3 days of SCI induced a strong proliferation of S100β+ astrocytes, OX-42+ microglia/macrophages and NG2+ cells. At this stage, the intense GFAP+ astrogliosis was BrdU negative. Twenty one days of SCI enhanced maturation of S100β+ cells into GFAP+ astrocytes, but decreased the number of CC1+ oligodendrocytes. Progesterone treatment inhibited astrocyte and microglia /macrophage proliferation and activation in the 3-day SCI group, and inhibited activation in the 21-day SCI group. BrdU/NG2 double labeled cells were increased by progesterone at 3 days, indicating a proliferation stimulus, but decreased them at 21 days. However, progesterone-enhancement of CC1+/BrdU+ oligodendrocyte density, suggest differentiation of OPC into mature oligondendrocytes. We conclude that progesterone effects after SCI involves: a) inhibition of astrocyte proliferation and activation; b) anti-inflammatory effects by preventing microglial activation and proliferation, and c) early proliferation of NG2+ progenitors and late remyelination. Thus, progesterone behaves as a glioactive factor favoring remyelination and inhibiting reactive gliosis.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704617     DOI: 10.1016/j.expneurol.2011.06.001

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  31 in total

Review 1.  Organotypic Spinal Cord Culture: a Proper Platform for the Functional Screening.

Authors:  Sareh Pandamooz; Mohammad Nabiuni; Jaleel Miyan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

Review 2.  Toll-like receptors in chronic pain.

Authors:  Lauren Nicotra; Lisa C Loram; Linda R Watkins; Mark R Hutchinson
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

3.  Neuroprotective Effects of Guanosine Administration on In Vivo Cortical Focal Ischemia in Female and Male Wistar Rats.

Authors:  Luciele Varaschini Teixeira; Roberto Farina Almeida; Francieli Rohden; Leo Anderson Meira Martins; Poli Mara Spritzer; Diogo Onofre Gomes de Souza
Journal:  Neurochem Res       Date:  2018-05-31       Impact factor: 3.996

Review 4.  Pregnancy, postpartum and parity: Resilience and vulnerability in brain health and disease.

Authors:  Nicholas P Deems; Benedetta Leuner
Journal:  Front Neuroendocrinol       Date:  2020-01-24       Impact factor: 8.606

5.  Emerging molecular therapeutic targets for spinal cord injury.

Authors:  Shuo Wang; George M Smith; Michael E Selzer; Shuxin Li
Journal:  Expert Opin Ther Targets       Date:  2019-09-04       Impact factor: 6.902

Review 6.  It's a lipid's world: bioactive lipid metabolism and signaling in neural stem cell differentiation.

Authors:  Erhard Bieberich
Journal:  Neurochem Res       Date:  2012-01-14       Impact factor: 3.996

Review 7.  Neurosteroidogenesis Today: Novel Targets for Neuroactive Steroid Synthesis and Action and Their Relevance for Translational Research.

Authors:  P Porcu; A M Barron; C A Frye; A A Walf; S-Y Yang; X-Y He; A L Morrow; G C Panzica; R C Melcangi
Journal:  J Neuroendocrinol       Date:  2016-02       Impact factor: 3.627

8.  Progesterone reduces secondary damage, preserves white matter, and improves locomotor outcome after spinal cord contusion.

Authors:  Daniel Garcia-Ovejero; Susana González; Beatriz Paniagua-Torija; Analía Lima; Eduardo Molina-Holgado; Alejandro F De Nicola; Florencia Labombarda
Journal:  J Neurotrauma       Date:  2014-05-01       Impact factor: 5.269

9.  Progesterone Changes VEGF and BDNF Expression and Promotes Neurogenesis After Ischemic Stroke.

Authors:  Chao Jiang; Fangfang Zuo; Yuejuan Wang; Hong Lu; Qingwu Yang; Jian Wang
Journal:  Mol Neurobiol       Date:  2016-01-08       Impact factor: 5.590

10.  5α-reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 Tat.

Authors:  Jason J Paris; ShiPing Zou; Yun K Hahn; Pamela E Knapp; Kurt F Hauser
Journal:  Brain Behav Immun       Date:  2016-01-13       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.